Differences between homoeopathic immunotherapy trials by Lewith et al and Reilly et al

     

    Lewith et al1

    Reilly et al2

    Possible implications

    Research context and stage of inquiry

    1st pilot of new design for HIT in asthma

    One of a series of 4 trials using HIT and allergy as a model

    Lewith et al inquiry needs a second phase

    Aims

    Evaluate efficacy of HIT in asthma

    Evaluate placebo hypothesis of homoeopathy

    Different questions

    Clinical context

    Primary care patients (38 practices)

    Specialist care patients (one centre for investigation of respiratory disease)

    Different patient group, different illness severity, different context effects

    Design bias

    Effectiveness—long clinical observation in the real world of primary care application

    Efficacy—highly focused, intense, short observation to ensure internal validity

    Lewith et al showed effectiveness but could not show efficacy; Reilly et al is the opposite

    Conventional diagnosis of asthma

    Clinic criteria, symptoms, and simple respiratory tests

    As for Lewith et al’s trial plus laboratory confirmation with histamine provocation testing

    Lewith et al’s trial OK for an effectiveness study but Reilly et al’s trial had more accurate selection for an efficacy study

    Basis of the homoeopathic diagnosis for the HIT prescription

    Conventional practitioners’ decisions

    Homoeopathic expert with 15 years’ experience of using HIT. Case conference for every case; respiratory and homoeopathic physicians able to bar entry to study

    Reilly et al’s trial had more accurate prescribing; expert decided in cases of ambiguity–for example, when skin reaction weal for house dust mite is equal to a competing allergen

    Treatment regimen and observation period

    Three doses over 24 hours; no repetition over next 16 weeks

    Three doses over 24 hours, observed for 4 weeks. In optional 4 week extension period patients given repeat doses at 4 weeks (that is, usual clinical practice)

    Likely inadequate treatment regimen in Lewith et al’s trial. Data at 4 weeks after randomisation should be explored

    Baseline data

    Off placebo

    On placebo

    Radically different context effects and baseline

    Data collection

    Discontinuous data

    Continuous data

    Unknown impact; patient liable to "reset" to recent baseline after a break ("poor memory of pain")

    Seasonal effects in exposure to house dust mite

    Recruitment timing begins 5 months before Reilly et al’s trial and lasts for 30-32 weeks. Wide geographical spread?

    After February and restricted to 4 weeks. Patients from restricted geographic zone

    Reilly et al’s trial has more even exposure; avoids winter peak of house dust mites as HIT will be less effective when seasonal challenge is maximal. May have avoided aggravations

    Outcome measures

    "Wider"; discontinuous; visual analogue scale labelled about asthma, different from that in Reilly et al’s study

    "Focused; continuous; visual analogue scale worded differently from Lewith et al’s study ("Overall today I felt¼")

    Different, so comparison problematic. All 4 HIT trials by Reilly and Taylor et al kept the wording steady

    Blinding

    A/B labelling, with research nurse and patient recording this

    Double coded individualised numbering

    Possibility in Lewith et al’s trial of researchers developing and transmitting conscious and unconscious attitudes

    Study power and risk of false negative result (type II error)

    Pilot study with best guess power calculation. Underpowered. High placebo response so high risk of a false negative result. No post hoc power calculation

    Based on previous trial in the series. Underpowered yet shows a positive result, so no risk of a false negative result

    Lewith et al’s trial may have false negative result

    Outcome

    Good result in both groups. Shows effectiveness, not efficacy, against large non-specific placebo clinical gain. Groups showed different response patterns–possible aggravations mixed with improvements

    Good result only with active treatment. Apparently poorer placebo response

    Placebo enhanced in Lewith et al’s trial. Placebo run-in qualification period in Reilly et al’s trial screened out and corrected for initial placebo effects, increasing power of the study

    HIT = Homoeopathic immunotherapy. VAS = Visual analogue scale.


 



Access jobs at BMJ Careers
Whats new online at Student 

BMJ